EVAR术后瘤囊未回缩与长期生存率降低相关
基于血管质量倡议(VQI)2003至2017年30,074例EVAR患者中14,817例有1年影像学随访者的回顾性分析,发现1年时40%瘤囊回缩、35%稳定、25%扩张;任何瘤囊未回缩(稳定或扩张)均与长期死亡率升高独立相关,且不依赖于内漏或再干预。
要点
- EVAR术后1年瘤囊未回缩(稳定或扩张)与长期死亡率升高独立相关。
- 瘤囊扩张与新生内漏风险增加相关(OR 2.3),稳定瘤囊亦相关(OR 3.1)。
- 他汀治疗与瘤囊扩张风险降低相关(OR 0.83),可能为可干预因素。
核心结论
- EVAR术后瘤囊行为与新生内漏、再干预及长期死亡率相关。
- 不仅瘤囊扩张,任何瘤囊未回缩均与长期死亡率升高独立相关,且不依赖于再干预或内漏。
- 他汀治疗可能改变瘤囊行为,但需进一步研究稳定瘤囊患者是否可从选择性再干预中获益。
研究设计与样本
- 回顾性队列研究,纳入血管质量倡议(VQI)2003至2017年所有接受EVAR且有术后1年(±6个月)影像学检查的患者。
- 共30,074例EVAR患者中14,817例(49%)纳入分析。
- 采用分层逻辑回归确定瘤囊行为、新生内漏和再干预的独立预测因素,Cox回归分析瘤囊行为与长期生存的关联,并进行倾向性匹配作为二次分析。
主要发现
- 1年时40%瘤囊回缩,35%稳定,25%扩张。
关键数值与推荐
- 瘤囊变化根据血管外科学会(SVS)指南定义(变化≥5 mm)。
- 瘤囊扩张定义为直径增加≥5 mm,回缩定义为直径减少≥5 mm,稳定为变化<5 mm。
临床怎么用
- EVAR术后1年影像学随访中应关注瘤囊是否回缩,未回缩(稳定或扩张)提示长期生存预后较差。
- 对于瘤囊稳定的患者,需警惕新生内漏风险,并考虑进一步评估和个体化随访。
- 他汀治疗与瘤囊扩张风险降低相关,可作为围手术期管理的参考。
局限性
- 回顾性研究设计,存在选择偏倚和未测量混杂因素。
- 仅49%的EVAR患者有1年影像学随访,可能影响代表性。
- 瘤囊稳定患者是否可从选择性再干预中获益尚需进一步研究。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: The early survival advantage of endovascular aneurysm repair (EVAR) compared with open repair reverses over time, possibly because of higher rates of reintervention related to endoleaks and aneurysm sac expansion. Therefore, we sought to examine the association between sac behavior, endoleaks, reintervention, and long-term survival. METHODS: We reviewed all patients undergoing EVAR in the Vascular Quality Initiative between 2003 and 2017 with an imaging study at 1 year postoperatively (±6 months). We defined aneurysm sac changes by Society for Vascular Surgery guidelines (change ≥5 mm) and determined independent predictors of sac behavior, new endoleak, and reintervention using hierarchical logistic regression. We employed Cox regression to examine the association between sac behavior and long-term survival. We performed propensity matching between patients with sac regression and those with failure to regress as a secondary analysis. RESULTS: Of 30,074 EVAR patients, 14,817 (49%) had a 1-year imaging study and were included in this study. At 1 year, 40% of sacs regressed, 35% remained stable, and 25% expanded. Factors independently associated with sac expansion were age (by decade: odds ratio [OR], 1.07; 95% confidence interval [CI], 1.01-1.13; P = .02), appearance of new endoleak (OR, 1.23; 95% CI, 1.10-1.37; P = .001), smaller aortic diameter (diameter <5 cm: OR, 1.37; 95% CI, 1.21-1.55; P < .001), anemia (OR, 1.47; 95% CI, 1.20-1.80; P < .001), rupture (OR, 1.33; 95% CI, 1.07-1.65; P = .01), and chronic kidney disease (OR, 1.15; 95% CI, 1.05-1.25; P < .01), whereas former smoking (OR, 0.86; 95% CI, 0.76- 0.96; P < .01), cerebrovascular disease (OR, 0.82; 95% CI, 0.67-0.99; P = .04), and statin therapy at discharge (OR, 0.83; 95% CI, 0.75-0.91; P < .001) were associated with lower risk of expansion. Both sac expansion (OR, 2.3; 95% CI, 2.0-2.7; P < .001) and a stable sac (OR, 3.1; 95% CI, 2.7-3.5; P < .001) were associated with the development of new endoleaks. Any failure of the aneurysm sac to regress was associated with long-term mortality compared with sac regression (stable sac size: hazard ratio, 1.2; 95% CI, 1.03-1.4; P = .02; sac expansion: hazard ratio, 1.6; 95% CI, 1.3-2.1; P < .001). This association persisted in patients without documented endoleaks and remained robust after accounting for reinterventions and endoleaks seen in follow-up or on completion angiography. In the propensity-matched cohort, patients with failure to regress experienced lower long-term survival (77% at 10 years compared with 82% for patients with sac regression; P = .01). CONCLUSIONS: After EVAR, aneurysm sac behavior is associated with the development of new endoleaks, reintervention, and long-term mortality. Not only sac expansion but any failure of the sac to regress is associated with higher long-term mortality, independent of reinterventions or endoleaks, and may be modified by statin therapy. Further study is needed to establish whether patients with stable sacs could benefit from selective reintervention.
引用
- O'Donnell TFX, Deery SE, Boitano LT, et al. Aneurysm sac failure to regress after endovascular aneurysm repair is associated with lower long-term survival. J Vasc Surg. 2018. PMID: 30686337. doi:10.1016/j.jvs.2018.04.050
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。